Aurora CO 脑肿瘤临床试验
9项针对 脑肿瘤的研究正在 Aurora及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- University of Colorado - Aurora Cancer Center, Aurora
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
招募中2 期
- Local Institution - 0182, Aurora
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
招募中2 期
- Rocky Mountain Cancer Centers-Aurora, Aurora
- University of Colorado Hospital, Aurora
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- University of Colorado Cancer Center, Aurora
Targeted Pediatric High-Grade Glioma Therapy
招募中观察性研究
- Children's Hospital Colorado, Aurora
Study of Olutasidenib and Temozolomide in HGG
招募中2 期
- Children's Hospital Colorado, Aurora
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
招募中2 期
- University Of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
招募中2 期
- Children's Hospital Colorado, Aurora
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
招募中1/2 期
- University of Colorado Cancer Center, Aurora
其他城市的 脑肿瘤试验
- Houston, TX35 项研究
- Boston, MA28 项研究
- New York City, NY25 项研究
- Washington, DC20 项研究
- Los Angeles, CA16 项研究
- Miami, FL15 项研究
- Durham, NC14 项研究
- St. Louis, MO12 项研究
- Rochester, MN12 项研究
- Columbus, OH11 项研究
- Baltimore, MD11 项研究
- Chicago, IL11 项研究
Aurora的其他研究
- 癌症（所有类型）35 项研究
- 结直肠癌32 项研究
- 非小细胞肺癌30 项研究
- 乳腺癌26 项研究
- 转移性癌症25 项研究
- 卵巢癌24 项研究
- 1型糖尿病23 项研究
- 肥胖症21 项研究
- 肺癌19 项研究
- 黑色素瘤18 项研究
- 心力衰竭18 项研究
- 前列腺癌17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。